tetano
Editor, Senior Moderator
Neurol Perspect
. 2022 Oct-Dec;2(4):232-239.
doi: 10.1016/j.neurop.2022.06.004. Epub 2022 Jun 30. Guillain-Barré syndrome associated with SARS-CoV-2 infection: A case series from 4 Colombian cities during the pandemic
N Cerón Blanco[SUP] 1 2 [/SUP], J H Rodríguez Quintana[SUP] 1 3 4 5 [/SUP], M C Valencia Mendoza[SUP] 1 2 [/SUP], C A Forero Botero[SUP] 6 [/SUP], L C Rodríguez[SUP] 7 [/SUP], S Carrillo Villa[SUP] 8 9 [/SUP], A M Gómez Mazuera[SUP] 10 [/SUP], J A Angarita Díaz[SUP] 11 12 13 [/SUP], B Uribe García[SUP] 14 15 [/SUP], C C Bermúdez Riveros[SUP] 1 4 [/SUP], J Alban[SUP] 12 [/SUP]
Affiliations
in English, Spanish
SARS-CoV-2 infection has been associated with multiple neurological manifestations. One such manifestation, which has been described since the early stages of the COVID-19 pandemic and is relevant for current neurological practice, is Guillain-Barré syndrome (GBS). The literature describes neurotoxic mechanisms of the virus itself and the possible pathways by which it may affect the peripheral nerves in experimental studies; however, we still lack information on the mechanisms causing the immune response that gives rise to GBS in the context of SARS-CoV-2 infection. Colombia is one of the Latin American countries worst affected by the pandemic, with the third-highest number of cases in the region; thus, it is essential to recognise GBS, as this potential postinfectious complication may severely compromise the patient's functional status in the absence of timely diagnosis and treatment. We present a series of 12 cases of GBS associated with SARS-CoV-2 infection from hospitals in 4 different Colombian cities and describe the clinical presentation, laboratory and electrophysiological study findings, and treatment.
Keywords: Acute polyneuropathy; Coronavirus; Guillain-Barré syndrome; Immunoglobulin; SARS-CoV-2; Weakness.
. 2022 Oct-Dec;2(4):232-239.
doi: 10.1016/j.neurop.2022.06.004. Epub 2022 Jun 30. Guillain-Barré syndrome associated with SARS-CoV-2 infection: A case series from 4 Colombian cities during the pandemic
N Cerón Blanco[SUP] 1 2 [/SUP], J H Rodríguez Quintana[SUP] 1 3 4 5 [/SUP], M C Valencia Mendoza[SUP] 1 2 [/SUP], C A Forero Botero[SUP] 6 [/SUP], L C Rodríguez[SUP] 7 [/SUP], S Carrillo Villa[SUP] 8 9 [/SUP], A M Gómez Mazuera[SUP] 10 [/SUP], J A Angarita Díaz[SUP] 11 12 13 [/SUP], B Uribe García[SUP] 14 15 [/SUP], C C Bermúdez Riveros[SUP] 1 4 [/SUP], J Alban[SUP] 12 [/SUP]
Affiliations
- PMID: 37521143
- PMCID: PMC9242699
- DOI: 10.1016/j.neurop.2022.06.004
in English, Spanish
SARS-CoV-2 infection has been associated with multiple neurological manifestations. One such manifestation, which has been described since the early stages of the COVID-19 pandemic and is relevant for current neurological practice, is Guillain-Barré syndrome (GBS). The literature describes neurotoxic mechanisms of the virus itself and the possible pathways by which it may affect the peripheral nerves in experimental studies; however, we still lack information on the mechanisms causing the immune response that gives rise to GBS in the context of SARS-CoV-2 infection. Colombia is one of the Latin American countries worst affected by the pandemic, with the third-highest number of cases in the region; thus, it is essential to recognise GBS, as this potential postinfectious complication may severely compromise the patient's functional status in the absence of timely diagnosis and treatment. We present a series of 12 cases of GBS associated with SARS-CoV-2 infection from hospitals in 4 different Colombian cities and describe the clinical presentation, laboratory and electrophysiological study findings, and treatment.
Keywords: Acute polyneuropathy; Coronavirus; Guillain-Barré syndrome; Immunoglobulin; SARS-CoV-2; Weakness.